Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that emodin from Polygonum multiflorum showed 5alpha-reductase inhibitory activity, which was more potent than alizarin but less potent than riboflavin.

This study found that finasteride-loaded microemulsions using poloxamer 124 significantly enhanced skin penetration of the drug compared to a standard solution, primarily through targeting hair follicles via the transfollicular pathway, with intercluster, intercellular, and transcellular pathways contributing less.

Finasteride effectively lowers specific hormone levels, helping monitor treatment progress.

This study found that dutasteride is more cost-effective compared to finasteride for treating benign prostatic hyperplasia in Montenegro, justifying its funding by the national health insurance fund.

This review critically evaluates the evidence for SARMs' tissue selectivity and suggests their clinical benefits over traditional androgens are not yet well-supported by robust evidence, underscoring the need for further head-to-head trials.

This review discusses hormonal manipulation for conditions like prostatic disorders and skin issues and highlights promising treatments like casodex and finasteride, but it reports no new clinical results.

More men are using medication for benign prostatic hyperplasia, influenced by marketing and FDA approvals.

This study found that Finasteride microemulsion gel significantly reduced acne lesions in men compared to a control treatment over three months.

This article reviews the use of cyproterone acetate for conditions like prostate cancer and sexual disorders, highlighting its effects on libido but reporting no new specific trial results.

This case report describes a 23-year-old woman with an adult granulosa cell tumor of the ovary, whose symptoms and hormone levels improved significantly after surgical removal of the tumor.

This study found that individualized GAHT regimens, including microdosing, effectively improved gender congruence and quality of life for non-binary individuals, but some experienced a decrease in bone mineral density.

This study found that the MorrF topical solution combination showed significantly better hair growth improvements than Minoxidil alone in male patients with Androgenetic Alopecia.

This study found that topical minoxidil 5% foam was effective in promoting hair growth in both the frontal and vertex scalp for men with androgenetic alopecia.

This study identified compounds 11d and 11k as potential dual 5α-reductase inhibitors and AR antagonists with significant anti-proliferative effects on prostate cancer cell lines, suggesting they may offer therapeutic value.

This article reflects on the history and significance of the FDA's approval of topical minoxidil for treating androgenetic alopecia in men and women, dating back to 1988 and 1991 respectively.

This study found that using monoolein cubic phase nanoparticles with an entrapped hydroxypropyl β-cyclodextrin/minoxidil complex increased minoxidil skin permeation, but minoxidil retention in the skin was higher with a traditional solution.

This study reported that a new polymeric formulation for topical minoxidil delivery in an animal model improved hair growth and hair follicle formation more effectively than minoxidil in PBS, suggesting potential as a future hair loss treatment.

This animal study found that Cinnamomi cortex water extract reduced prostate weight and improved histological changes in a benign prostatic hyperplasia model, suggesting potential as a treatment.

This study demonstrated that a finasteride-loaded proniosome significantly enhanced transfollicular delivery and hair growth in mice without causing skin irritation, with effects comparable to a 2% minoxidil solution.

In this study, G. brevis and M. myristica, alone or together, improved hematological and testicular antioxidant parameters in male rats with finasteride-induced reproductive toxicity, showing potential protective effects against oxidative stress and supporting therapeutic use for related male reproductive disorders.

In this study, once-daily 5% minoxidil foam and twice-daily 2% minoxidil solution both promoted hair regrowth in women with female pattern hair loss, but noninferiority of the foam was not established.

This review discusses the safety of finasteride for male androgenic alopecia and benign prostatic hyperplasia, concluding it remains a viable option due to synergistic effects with other treatments and predictive measures for side effect risk.

This study found that certain bioactive mushroom metabolites may inhibit the enzyme SRD5A2 more effectively than finasteride in computational models, suggesting potential for further research in treating androgenic alopecia.

This chapter reviews selective androgen receptor modulators, discussing their therapeutic potential beyond current androgen applications, and reports no new clinical findings.

In this study, finasteride was found to reduce cholesterol levels and delay atherosclerosis in LDL receptor-deficient mice, and men using finasteride reported lower cholesterol levels, suggesting potential cardiovascular benefits by improving lipid profiles.

Among patients diagnosed with hair loss at a Miami dermatology department, this study found that oral minoxidil prescriptions increased significantly among English-preferring patients six months after media attention, but not for Spanish-preferring patients or within three months for either group.

This study found that after 12 weeks of taking the trial product SHPro®, participants reported improvements in prostate symptom scores and erectile function, with confirmed safety.

This study found that dutasteride more effectively reduced serum dihydrotestosterone levels than finasteride in patients with benign prostatic hyperplasia.